All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Scorr-Insert

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

A collaboration with SCORR Marketing

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

Axon Neuroscience

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CYPRUS Cyprus

Post An Enquiry

BIO International Convention

Participation Not Confirmed

Update your events

Axon Presented Positive Phase II Trial Results of AADvac1 at AAT-AD/PD 2020

Contact the Supplier

Lead Product(s): AADvac1

Therapeutic Area: Neurology

Highest Development Status: Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 03, 2020

Details:

A highly significant impact on neurodegeneration was shown on brain proteins in plasma - Neurofilament Light Chain, and CSF - Tau and p-Tau, and Diffusion Tensor Imaging.